These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21967991)

  • 1. Results of a BoNT/A antibody study in children and adolescents after onabotulinumtoxin A (Botox®) detrusor injection.
    Schulte-Baukloh H; Herholz J; Bigalke H; Miller K; Knispel HH
    Urol Int; 2011; 87(4):434-8. PubMed ID: 21967991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.
    Hegele A; Frohme C; Varga Z; Olbert P; Kranz J; Hofmann R
    Urol Int; 2011; 87(4):439-44. PubMed ID: 22004911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity.
    Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1497-502. PubMed ID: 21717501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
    Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
    Kuo HC; Liao CH; Chung SD
    Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury.
    Munoz A; Somogyi GT; Boone TB; Smith CP
    Neurourol Urodyn; 2011 Sep; 30(7):1376-81. PubMed ID: 21509809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study.
    Schulte-Baukloh H; Priefert J; Knispel HH; Lawrence GW; Miller K; Neuhaus J
    Urology; 2013 May; 81(5):1052-7. PubMed ID: 23419459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a direct antimicrobial effect of botulinum neurotoxin type A?
    Wöllner J; Schmidig K; Gregorini F; Kessler TM; Zbinden R; Mehnert U
    BJU Int; 2012 Dec; 110(11 Pt C):E886-90. PubMed ID: 22882378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Liu HT; Chancellor MB; Kuo HC
    Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele.
    Horst M; Weber DM; Bodmer C; Gobet R
    Neurourol Urodyn; 2011 Nov; 30(8):1546-9. PubMed ID: 21674597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure.
    Schulte-Baukloh H; Bigalke H; Miller K; Heine G; Pape D; Lehmann J; Knispel HH
    Int J Urol; 2008 May; 15(5):407-15; discussion 415. PubMed ID: 18452456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity].
    Romero RM; Rivas S; Parente A; Fanjul M; Angulo JM
    Actas Urol Esp; 2011 Feb; 35(2):89-92. PubMed ID: 21256633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for bladder botulinum toxin application.
    Kim DK; Thomas CA; Smith C; Chancellor MB
    Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
    Pannek J; Göcking K; Bersch U
    BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?
    Tiburtius C; Böthig R; Kowald B; Hirschfeld S; Thietje R
    BMC Urol; 2020 Aug; 20(1):113. PubMed ID: 32741365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
    Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
    J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.